Nevro (NVRO) Tops Q4 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 4:05 PM ESTREDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.
Recent Highlights
Fourth Quarter 2020 Worldwide Revenue of $109.7 Million; Decrease of 4% Compared to Prior Year Fourth Quarter 2020 Net Loss from Operations of $0.9 Million; Fourth Quarter 2020 Non-GAAP Adjusted EBITDA of $15.7 Million Company Provides Full-Year 2021 Revenue Guidance of $430 Million to $450 Million Company... More